SS Innovations International (SSII) reported that its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console were used in a series of remote operations during two international medical conferences in October 2026. The demonstrations, which included a robotic-assisted cardiac procedure performed from approximately 7,500 miles away, signal a step toward making specialized surgical care accessible to patients regardless of geographic location, though widespread adoption will depend on clinical validation, connectivity, and regulatory approvals.
At the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, Dr. Sudhir Srivastava, chairman and CEO of SS Innovations, remotely performed an atrial septal defect procedure on a patient located in Bengaluru, India. The company also participated in the inaugural Society of Robotic Surgery India conference, where four additional robotic telesurgeries were performed or broadcast, covering urological, colorectal, pediatric, and gynecological procedures. As of October 23, 2026, the company reported 205 telesurgeries performed with the SSi Mantra system, including cardiac procedures. These events underscore the growing feasibility of remote robotic surgery, which could allow expert surgeons to operate on patients in underserved or remote areas, potentially reducing travel burdens and improving access to timely care.
The implications of these demonstrations are significant for the healthcare industry. If validated and adopted, telesurgery could help address shortages of specialized surgeons in certain regions and enable faster treatment for time-sensitive conditions. However, the company noted that widespread adoption depends on clinical validation, connectivity, and regulatory requirements. SS Innovations is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027, though the timeline remains subject to the FDA’s review.
For investors, the announcements highlight SS Innovations’ progress in advancing its robotic surgery platform and its efforts to enter the U.S. market. The company’s ability to demonstrate long-distance cardiac surgery may bolster its position in the competitive surgical robotics field. More details on the demonstrations are available through the company’s SS Innovations (NASDAQ: SSII) profile and the full announcement. The latest updates relating to SSII can be found in its newsroom at https://ibn.fm/SSII, and the original release is available via www.newmediawire.com.
